Evan Adelstein is a Cardiology physician affiliated with Albany Research Institute. OpenAlex indexes 161 publications with 3,169 citations (h-index 30); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
47 New Scotland Ave # Mc-44
Albany, NY 122083412
Telephone
182-625-0765Provider last certified this registry record 9 Mar 2022.
Clinical trials
- Acute Mechanical Response to Anti-arrhythmic Drug Therapy
Sponsor: Evan Adelstein, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year202511 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20255 payments
- Boston Scientific CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
72.2%Beta blocker34.6%Metoprolol Succinate58%Metoprolol Tartrate16%Sotalol14%Carvedilol11%Part D<11 patientsAntiarrhythmic25.8%Dofetilide42%Amiodarone Hcl34%Flecainide Acetate24%Part D<11 patients+ 2 more classes in this area
Blood & clotting
27.8%Factor Xa inhibitor27.8%Eliquis75%Xarelto25%Part D≥30 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death
JACC. Clinical electrophysiology
2019 - Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019
Cardiovascular Drugs and Therapy
2019 - Implantable Defibrillator Therapy in Cardiac Arrest Survivors With a Reversible Cause
Circulation Arrhythmia and Electrophysiology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”